Alnylam Reports Positive Phase II Data for ALN-TTR02, an RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR-Mediated Amyloidosis (ATTR) (Alnylam Pharmaceuticals Inc)

(Source: Alnylam Pharmaceuticals Inc) Alnylam Reports Positive Phase II Data for ALN-TTR02, an RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR-Mediated Amyloidosis (ATTR) - Interim Results in ATTR Patients Show up to 93% Knockdown of TTR with Activity toward Both Wild-Type and Mutant TTR - - Multiple Doses of ALN-TTR02 Generally Safe and Well Tolerated with Once-Every-Four-Week and Once-Every-Three-Week Dosing Regimens - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 30, 2013-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today the achievement of positive clinical results from its Phase II trial of ALN-TTR02, an RNAi...